PEDIATRICS Vol. 95 No. 6 June 1995, pp. 942-944
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rubaltelli, F. F.
Right arrow Articles by Zancan, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rubaltelli, F. F.
Right arrow Articles by Zancan, L.

Congenital Nonobstructive, Nonhemolytic Jaundice: Effect of Tin-Mesoporphyrin

Firmino F. Rubaltelli MD1, Cinzia Dario MD1, and Lucia Zancan MD1

1 Department of Pediatrics, University of Padova School of Medicine, Padova, Italy

Tin-protoporphyrin (SnPP) and tin-mesoporphyrin (SnMP) have been proposed for the treatment of Crigler-Najjar (CN) disease type 1;1,2 in fact, both drugs moderate the hyperbilirubinemia to some extent.1,2 These compounds bind to heme oxygenase far more avidly than does heme itself, thus blocking access of the natural substrate to the binding site of the enzyme and inhibiting heme degradation and bilirubin production.3-5 Because these synthetic compounds do not contain iron and thus cannot bind oxygen, they cannot be oxidatively transformed into bilirubin by the enzyme heme oxygenase and therefore remain intact until they are excreted.

Recently, SnPP was administered to a 2.5-month-old girl,1 and two 17-year-old boys were successfully treated with two cycles of prolonged SnMP therapy.2

Submitted on May 11, 1994
Accepted on September 28, 1994




This article has been cited by other articles:


Home page
 NeoReviewsHome page
R. J. Wong, V. K. Bhutani, H. J. Vreman, and D. K. Stevenson
Pharmacology Review: Tin Mesoporphyrin for the Prevention of Severe Neonatal Hyperbilirubinemia
NeoReviews, February 1, 2007; 8(2): e77 - e84.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
M. I. Shevell, A. Majnemer, and D. Schiff
Neurologic Perspectives of Crigler-Najjar Syndrome Type I
J Child Neurol, June 1, 1998; 13(6): 265 - 269.
[Abstract] [PDF]